Clinical Value of 99mTc-3PRGD2 SPECT/CT in Differentiated Thyroid Carcinoma with Negative 131I Whole-Body Scan and Elevated Thyroglobulin Level

[1]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[2]  K. Woliński,et al.  The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan , 2016, Nuclear medicine communications.

[3]  Wangfan,et al.  99mTc-3PRGD2 SPECT/CT Imaging for Monitoring Early Response of EGFR-TKIs Therapy in Patients with Advanced-Stage Lung Adenocarcinoma , 2016 .

[4]  Fan Wang,et al.  Integrin Imaging with 99mTc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non-Small Cell Lung Cancer. , 2016, Radiology.

[5]  Su Jung Choi,et al.  Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody , 2016, Nuclear Medicine and Molecular Imaging.

[6]  B. Torbett,et al.  Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream. , 2016, Thrombosis research.

[7]  Hui Wang,et al.  The effect of antagonizing RGD-binding integrin activity in papillary thyroid cancer cell lines , 2016, OncoTargets and therapy.

[8]  H. Kessler,et al.  Caveolin-1-negative head and neck squamous cell carcinoma primary tumors display increased epithelial to mesenchymal transition and prometastatic properties , 2015, Oncotarget.

[9]  Fan Wang,et al.  Utility of 99mTc-PEG4-E[PEG4-c(RGDfK)]2 in Posttherapy Surveillance of Patients with Reelevated Carcinoembryonic Antigen Levels , 2015, Medical Principles and Practice.

[10]  S. Polat,et al.  Diagnostic value of 18F-FDG PET/CT in patients with TENIS syndrome: correlation with thyroglobulin levels , 2014, Annals of Nuclear Medicine.

[11]  S. Lata,et al.  Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  K. Woliński,et al.  Comparison of Diagnostic Value of Conventional Ultrasonography and Shear Wave Elastography in the Prediction of Thyroid Lesions Malignancy , 2013, PloS one.

[13]  M. Salvatori,et al.  The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview , 2013, European Archives of Oto-Rhino-Laryngology.

[14]  Jun Liang,et al.  Integrin αvβ3 Imaging of Radioactive Iodine–Refractory Thyroid Cancer Using 99mTc-3PRGD2 , 2012, The Journal of Nuclear Medicine.

[15]  A. Alavi,et al.  Prognostic Significance of FDG PET/CT on the Follow-Up of Patients of Differentiated Thyroid Carcinoma With Negative 131I Whole-Body Scan and Elevated Thyroglobulin Levels: Correlation With Clinical and Histopathologic Characteristics and Long-Term Follow-Up Data , 2012, Clinical nuclear medicine.

[16]  Yang Zhou,et al.  99mTc-Labeled Cyclic RGD Peptides for Noninvasive Monitoring of Tumor Integrin αvβ3 Expression , 2011, Molecular imaging.

[17]  L. Allen,et al.  Monitoring Tumor Response to Antiangiogenic Sunitinib Therapy with 18F-Fluciclatide, an 18F-Labeled αVβ3-Integrin and αVβ5-Integrin Imaging Agent , 2011, The Journal of Nuclear Medicine.

[18]  E. Silberstein.  The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. , 2011, Seminars in nuclear medicine.

[19]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[20]  Shu-ye Yang,et al.  Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis , 2009, Nuclear medicine communications.

[21]  B. Felding-Habermann,et al.  Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain , 2009, Proceedings of the National Academy of Sciences.

[22]  W. Oyen,et al.  Guidelines for radioiodine therapy of differentiated thyroid cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  T. Low,et al.  Lymph Node Status Influences Follow-Up Thyroglobulin Levels in Papillary Thyroid Cancer , 2008, Annals of Surgical Oncology.

[24]  M. Schwaiger,et al.  Comparison of Integrin αvβ3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG , 2007, Journal of Nuclear Medicine.

[25]  M. Schwaiger,et al.  Integrin {alpha}v{beta}3 expression and glucose metabolism do not correlate in primary and metastatic lesions in cancer patients: A PET study using [18F]Galacto-RGD and [18F]FDG , 2007 .

[26]  L. Knight,et al.  Differences in Binding of 99mTc-Disintegrins to Integrin αvβ3 on Tumor and Vascular Cells , 2007 .

[27]  Stephanie L. Lee,et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[28]  E. Baudin,et al.  Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. , 2002, Thyroid : official journal of the American Thyroid Association.

[29]  A. Pinchera,et al.  Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. , 2001, The Journal of clinical endocrinology and metabolism.

[30]  P. V. van Rijk,et al.  Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results , 1999, European Journal of Nuclear Medicine.

[31]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[32]  F. F. Melacrinis,et al.  Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  G. Bieler,et al.  Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.

[34]  V. Roelants,et al.  The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer , 1997, European Journal of Nuclear Medicine.

[35]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[36]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.

[37]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[38]  Fan Wang,et al.  (99m)Tc-3PRGD2 SPECT/CT Imaging for Monitoring Early Response of EGFR-TKIs Therapy in Patients with Advanced-Stage Lung Adenocarcinoma. , 2016, Cancer biotherapy & radiopharmaceuticals.

[39]  Mai Hong Son,et al.  Value of Dedicated Head and Neck 18F-FDG PET/CT Protocol in Detecting Recurrent and Metastatic Lesions in Post-surgical Differentiated Thyroid Carcinoma Patients with High Serum Thyroglobulin Level and Negative 131I Whole-body Scan , 2016, Asia Oceania journal of nuclear medicine & biology.

[40]  Marek Ruchała,et al.  Usefulness of different ultrasound features of malignancy in predicting the type of thyroid lesions: a meta-analysis of prospective studies. , 2014, Polskie Archiwum Medycyny Wewnetrznej.

[41]  S. Lata,et al.  Prospective evaluation of 68 Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131 I-whole body scan: comparison , 2014 .

[42]  DipSci MBChB Dch Fracp MM Kevin London BHB,et al.  Clinical and Pathological Factors Related to 18F-FDG-PET Positivity in the Diagnosis of Recurrence and/or Metastasis in Patients with Differentiated Thyroid Cancer , 2010, Annals of Surgical Oncology.

[43]  Jin Wu-dong.  Comparison with ~(18)F-FDG PET-CT,MRI and spiral CT in detection of primary liver carcinoma lesions , 2008 .

[44]  L. Knight,et al.  Differences in binding of (99m)Tc-disintegrins to integrin alphavbeta3 on tumor and vascular cells. , 2007, Nuclear medicine and biology.

[45]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[46]  J. Plukker,et al.  Implications of mediastinal uptake of 131I with regard to surgery in patients with differentiated thyroid carcinoma , 2005, Cancer.

[47]  R. Buchert,et al.  Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  G. Bieler,et al.  Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. , 1998, Nature medicine.

[49]  N. Sobol,et al.  Preliminary results , 2020, Asymptotic Analysis of Random Walks: Light-Tailed Distributions.